Marshall Wace’s RAPT Therapeutics RAPT Stock Holding History

Marshall Wace’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-84,596	Closed	-$2.87M	–	3599
2025 Q4	$2.87M	Buy	84,596 +67,751	+402%	+$2.1M	﹤0.01%	1411
2025 Q3	$434K	Buy	+16,845	New	+$220K	﹤0.01%	2286
2024 Q1	–	Sell	-2,766	Closed	-$550K	–	2745
2023 Q4	$550K	Buy	+2,766	New	+$342K	﹤0.01%	1690
2022 Q1	–	Sell	-13,684	Closed	-$4.02M	–	3901
2021 Q4	$4.02M	Sell	13,684 -1,328	-9%	-$355K	0.01%	1529
2021 Q3	$3.73M	Buy	15,012 +5,319	+55%	+$1.41M	0.02%	1133
2021 Q2	$2.46M	Buy	+9,693	New	+$1.81M	0.01%	1282

Marshall Wace's RAPT Position: Q1 2026 in Review

Marshall Wace sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 84,596 shares — an estimated $2.87M sold.

Marshall Wace first reported a position in RAPT in Q2 2021 and held it in 6 quarters. The position peaked at $4.02M in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Marshall Wace reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Marshall Wace sold 84,596 RAPT Therapeutics shares in Q1 2026, an estimated $2.87M.
Marshall Wace first reported a position in RAPT Therapeutics in Q2 2021 and held it in 6 quarters.
Marshall Wace's RAPT Therapeutics position peaked at $4.02M in Q4 2021.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.